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References 74AbstractThe molecular clock consists of a number of genes that form transcriptional and post-
transcriptional feedback loops, which function together to generate circadian oscilla-
tions that give rise to circadian rhythms of our behavioral and physiological
processes. Genetic variations in these clock genes have been shown to be associated
with phenotypic effects in a repertoire of biological processes, such as diurnal prefer-
ence, sleep, metabolism, mood regulation, addiction, and fertility. Consistently, rodent
models carrying mutations in clock genes also demonstrate similar phenotypes. Taken
together, these studies suggest that human clock-gene variants contribute to the phe-
notypic differences observed in various behavioral and physiological processes,51
52 Luoying Zhang et al.although to validate this requires further characterization of the molecular conse-
quences of these polymorphisms. Investigating the diversity of human genotypes
and the phenotypic effects of these genetic variations shall advance our understanding
of the function of the circadian clock and how we can employ the clock to improve our
overall health.1. INTRODUCTION
The circadian clock regulates daily rhythms of behavior and physiol-ogy in organisms ranging from bacteria to human,1 with the daily sleep and
wake cycle in animals being one of the most prominent functions regulated
by the clock. An intact clock enables the organism to adjust its biological
processes to anticipate daily changes in the environment, whereas a
disrupted clock underlies various disorders and/or diseases.2
Our understanding of the human molecular clock is largely based
on studies in rodents and in vitro. The molecular clock consists of a series
of transcriptional/posttranscriptional feedback loops with Clock and Bmal1
at the center of the loops.3 CLOCK/BMAL1 dimers activate the transcrip-
tion of three Period genes (Per1, 2, and 3) and two Cryptochrome genes (Cry1
and Cry2). PER and CRY heterodimerize and translocate into the nucleus,
inhibiting the transcriptional activity of CLOCK/BMAL1. In a second
loop, CLOCK/BMAL1 activates the transcription of retinoic acid-related
orphan receptors,Rev-erba andRora. The former inhibits, whereas the latter
activates transcription of Bmal1. In certain tissues, neuronal PAS domain
protein 2 (NPAS2) functions as a CLOCK analog.4 CLOCK and BMAL1
are also believed to drive the expression ofDec1 andDec2, which function to
repress the transactivation of CLOCK/BMAL1 at clock-gene promoters.5,6
In addition, DBP and E4BP4 are clock-controlled positive and negative reg-
ulators, respectively, of D-boxes in the promoter regions of clock genes.7–9
TIMELESS may also function in the clock by associating with PER/CRY
and inhibiting CLOCK/BMAL1-stimulated transcription of Per.10
Besides transcriptional control, posttranslational modifications also play a
critical role in setting the speed of clock. Casein kinase 1 epsilon (CK1e) and
casein kinase 1 delta (CK1d) impinge on the negative limb of the feedback
loop by phosphorylating PERs, resulting in enhanced protein turnover and
nuclear translocation, which in turn affects the transactivation by CLOCK/
BMAL1.11 Mutation in Ck1e dramatically shortens the period of circadian
rhythms in both hamster and mouse.12,13 Consistently, a mutation in CK1d
53Phenotypic Effects of Human Clock Polymorphismsresults in familial advanced sleep phase (FASP) in humans and shorter period
in a transgenic mouse model.14 One route that phosphorylation impinges on
protein turnover is to target the substrate for ubiquitylation and degradation
by the 26S proteasome. CK1-mediated phosphorylation of PER leads to
recruitment of Skp1-Cul1-F-box protein ubiquitin ligase and a ubiquitin
ligase adaptor protein, b-transducin repeat protein (b-TrCP), leading to
ubiquitylation, and degradation of PER.15–17 Similarly, an F-box protein
FBXL3 regulates the degradation of CRY.18–20
Genetic variations of these clock genes can contribute to physiological
changes, which ultimately lead, in some cases, to alterations in disease sus-
ceptibility. In this chapter, we bring together findings from studies that
examine the effects of human clock-gene variations on diverse aspects of
behavior and physiology such as sleep, mood, metabolism, and cancer.
2. BMAL1
BMAL1 variants may play a causative role in type 2 diabetes (T2D)and hypertension. A genetic association study that examined 1304 individ-
uals from 424 families primarily selected for T2D demonstrates that two
BMAL1 haplotypes are associated with T2D and hypertension.21 Similarly
in rodents, Bmal1 is located within hypertension susceptibility loci and maps
closely to a region that is genetically divergent between normotensive and
spontaneously hypertensive rat.21 Cell culture experiments revealed that a
polymorphism in Bmal1 promoter significantly affects transcriptional activa-
tion by GATA-4, which is a transcription factor known to be expressed in
the cardiovascular system.21 Therefore, this polymorphism could potentially
affect Bmal1 expression in tissues that are critical for regulating blood pres-
sure. Moreover, Bmal1 mutant mice show defects in glucose tolerance,
reduced islet size, islet proliferation, and insulin secretion that worsen with
age, consistent with genetic association studies in human.22 Conditional
knockout mice with Bmal1 deficiency specifically in the pancreas exhibit
diabetes mellitus due to impaired beta-cell function at the latest stage of
stimulus-secretion coupling.22 Notably, one of the single-nucleotide poly-
morphisms (SNPs) identified in the human haplotype associated with T2D is
also significantly associated with susceptibility to prostate cancer.23
BMAL1 has been implicated in the pathogenesis of seasonal affective dis-
order (SAD). SNP analysis in 189 patients and 189matched controls found an
intronic variation inBMAL1 to be associatedwithwinter depression. Based on
in silico studies, this site may affect the binding of transcription factors.24
54 Luoying Zhang et al.Furthermore, this variation correlateswith differences in experiencing seasonal
variation of energy levels.25
BMAL1may contribute to fertility. An intronic polymorphism has been
shown to link to the number of pregnancies and miscarriages.25 This is in
agreement with studies in Bmal1-null mutant mice, which demonstrates that
Bmal1 is necessary for fertility.26,27 Loss of Bmal1 in male mice results in
reduced testosterone production,26 while in female mice, Bmal1 deficiency
leads to impaired growth and development of the reproductive system,
reduced ovulation rate, and failure of fertilized oocytes to implant.27
Lastly, a study investigating whether clock-gene polymorphisms predis-
pose to alcohol use identified an intronic variant in BMAL1 to be associated
with alcohol consumption in socially drinking controls but not in individuals
with alcohol dependence or abuse.28
3. CLOCK
The first polymorphism identified in clock genes to be associated withhuman phenotypes is a SNP located in the 30-untranslated region (UTR) of
CLOCK, rs1801260 A/G. Subjects carrying the G allele have significantly
lower scores on the Horne–O¨steberg (HO¨) questionnaire, which assays
morningness/eveningness preference and a lower score means eveningness
is preferred.29 The G allele carriers show 10- to 44-min delay in preferred
timing for active and sleep phases. This finding of rs1801260 G allele asso-
ciating with evening preference was further validated by independent inves-
tigations.30–32 However, there are also several studies that were not able to
observe this association between the G allele and eveningness, which may be
due to differences in ethnic heritages and/or linkages to other polymor-
phisms (reviewed in Refs. 33 and 34).
Apart from playing a central role in the circadian clock, CLOCK is
believed to participate in the regulation of sleep as well. Based on HO¨ ques-
tionnaire, rs1801260 G/G homozygotes show significantly shorter sleep
duration and increased daytime sleepiness compared to individuals carrying
the A allele.30,32,35 The association of rs1801260 and sleep has also been
observed in patients with psychiatric disorders. Among patients with major
depressive disorder (MDD) or bipolar disorder (BP), G/G homozygotes
exhibit significantly increased occurrence of sleep disturbance and BP
patients that are homozygous of the G allele show decreased need for sleep.36
rs1801260 G/G homozygotes also demonstrate higher presence of insomnia
during antidepressant treatment.37 Moreover, in patients with major
55Phenotypic Effects of Human Clock Polymorphismspsychosis (mainly schizophrenia), rs1801260 G/G correlates with daytime
sleepiness induced by clozapine treatment, suggesting an interaction
between clozapine and CLOCK rs1801260 polymorphism.38 Besides the
much studied rs1801260 SNP, two variants in the intronic regions of
CLOCK have also been shown to be associated with sleep duration based
on assessment using Munich ChronoType Questionnaire.39 Consistently,
mutation in theClock gene alters sleep homeostasis in mice.40 Heterozygous
and homozygous Clock mutant mice sleep approximately 1 and 2 h less,
respectively, than wild type. The heterozygous and homozygous mutants
also show 25% and 51% smaller increase of rapid eye movement (REM)
sleep, respectively, during 24 h recovery sleep relative to wild-type mice.
Given the reciprocal connections between circadian rhythms/sleep and
psychiatric disorders, a number of studies searched for association of
CLOCK gene polymorphisms with mood. The much studied rs1801260
G allele exhibits significant association with BP,41 and in patients with over
5 years of BP history, recurrence rate for bipolar depression is significantly
higher in rs1801260 G/G homozygotes.42 Two variants downstream of the
CLOCK gene are also significantly linked to BP.43,44 In BP and unipolar
patients undergoing a depressive episode, rs1801260 is related to neuropsy-
chological performance and neural responses in the cingulate cortex to stim-
uli with moral valence.31 In addition, the rs1801260 G allele has been shown
to be associated with schizophrenia.45 Interestingly, the rs1801260 A allele
significantly correlates with attention deficit hyperactivity disorder
(ADHD), implicating a protective role of the G allele in this disorder.46,47
A synonymous polymorphism in exon 20 of the CLOCK gene is linked to
fluvoxamine therapeutic response inMDD patients as well as remission with
fluvoxamine,48 implying interaction between the CLOCK polymorphism
and the mechanistic actions of fluvoxamine. Again these findings are con-
sistent with studies inClockmutant mice. These mice exhibit overall behav-
ioral profile similar to human mania, including hyperactivity, decreased
sleep, reduced depression-like and anxiety-like behaviors, as well as an
increase in the reward value for cocaine, sucrose, and medial forebrain bun-
dle stimulation.49,50 Chronic administration of the mood stabilizer lithium
can bring many of these behavioral phenotypes back to wild-type levels.49
The mutant animals exhibit increased dopaminergic activity in the ventral
tegmental area, a key reward region in the brain, which could lead to the
phenotypes.49,50 Taken together, these findings in mice are in agreement
with the human studies and corroborate the notion that CLOCK is involved
in mood regulation.
56 Luoying Zhang et al.Similar to BMAL1, CLOCK has also been suggested to play a role in
metabolic processes. A number of CLOCK polymorphisms are related to
body mass index (BMI). Two of these variants located in intron
12 (rs1554483) and the promoter region of the CLOCK gene
(rs4864548) form a haplotype associated with BMI, while two additional
variants, rs1801260 and rs3749474 (located in 30-UTR), are individually
associated with BMI.35,51,52 Both rs1801260 and rs3749474 are significantly
associated with weight, and the latter with waist circumference as well.35
Under weight-reduction programs, rs1801260 G allele carriers display
greater difficulty losing weight, higher plasma ghrelin levels, altered eating
behavior, and dietary habits compared to the noncarriers.32,35 Both
rs1801260 and rs3749474, along with an additional SNP in intron 9,
rs4580704, are significantly linked to changes in serum cholesterol at the
end of dietary treatment.35 In contrast to overweight/obese individuals,
patients with anorexia nervosa or bulimia nervosa carrying the rs1801260
G allele have a lifetime body weight significantly lower than those carrying
the A/A genotype, implying a rather complex mechanism of how this
rs1801260 variant interacts with metabolism.53 Notably, rs1801260
G carriers exhibit significantly less small dense low-density lipoprotein, an
abnormal lipid metabolite and one of the risk parameters for cardiometabolic
disorders, compared to individuals with rs1801260 A/A.54 Several SNPs in
the CLOCK gene are significantly associated with energy intake, including
the aforementioned 30-UTR SNP rs3749474, intron 9 SNP rs4580704,
promoter SNP rs4864548, and an SNP in intron 11.35 Moreover,
rs3749474, rs4580704, and rs1801260 are related to plasma cytokine levels,
particularly those that highly correlated with energy intake.35 These energy
intake-associated SNPs, including rs1801260, are also linked to the mono-
unsaturated fatty acid content of red blood cell membrane, which plays a
critical metabolic role.55 rs4580704 and rs1801260 exhibit dietary fatty
acid-dependent associations with metabolic syndrome traits including glu-
cose and insulin resistance as well as waist circumference.55 This suggests that
CLOCK polymorphisms interact with fatty acid to modulate metabolic pro-
cesses. In addition, rs4580704 is significantly associated with the risk of
hypertension.55 A number of SNPs in the promoter and intronic regions
of CLOCK show significant associations with susceptibility to and severity
of nonalcoholic fatty liver disease, which is one of the most common abnor-
malities observed in obese people.56 Two of these SNPs, promoter SNP
rs4864548 and intron 12 SNP rs1554483, have been reported to be linked
with BMI and energy intake as described earlier, adding further evidence
57Phenotypic Effects of Human Clock Polymorphismssuggesting a role for CLOCK in metabolic pathways. Clock mutant mice
nicely recapitulate many of themetabolic phenotypes associated with human
CLOCK gene polymorphisms. These animals are hyperphagic and obese
and develop hyperleptinemia, hyperlipidemia, hepatic steatosis, hyperglyce-
mia, and hypoinsulinemia.57 This supports the idea that the polymorphisms
in the human CLOCK gene are causatively linked to metabolic alterations
observed in human subjects.
Lastly, CLOCK variants correlate with the risk and survival rate of can-
cer. Several SNPs located in intronic regions and 30-UTR of CLOCK,
including rs1801260, are significantly associated with susceptibility to pros-
tate cancer or breast cancer.23,58,59 Both rs1801260 and rs3749474, which
have been implicated in various metabolic traits as described earlier, exhibit
significant association with survival of colorectal cancer.604. NPAS2
As a paralogue of CLOCK, NPAS2 has also been implicated in circa-dian timing and sleep. A SNP in intron 3 of the NPAS2 gene is associated
with timing of sleep in nurses on shift-work schedule, while another SNP in
intron 3 correlates with sleepiness during shift work and self-reported adap-
tation levels to shift-work schedule.61 Notably, this latter SNP is also signif-
icantly linked to alcohol consumption.61 Consistently,Npas2-deficient mice
show reduction in sleep during the active phase and enhanced adaptability to
phase advance of light–dark schedule.62
Like the other two circadian activators, BMAL1 and CLOCK, NPAS2
may be involved in mood regulation as well. In patients with SAD, the fre-
quency ofNPAS2 471 Leu/Leu genotype is significantly higher than in con-
trols, suggesting that NPAS2 471 Leu/Leu contributes to disease
susceptibility.24,63 Furthermore, NPAS2 394 Thr correlates with lack of
experiencing seasonal variation, assayed by Global Seasonal Scores which
measures six items, including seasonal variation of sleep length, social activ-
ity, mood, weight, appetite, and energy level, whereas an intronic variant of
NPAS2 is associated with seasonal variation of weight.25 Another intronic
SNP is related to the number of miscarriages, implying that NPAS2 influ-
ences fertility.25 Intronic polymorphisms inNPAS2 have also been linked to
unipolar major mood depression, autistic disorder, and chronic fatigue syn-
drome.44,64,65 Notably, NPAS2 expression is increased in patients with
chronic fatigue syndrome.65
58 Luoying Zhang et al.A missense polymorphism in NPAS2, 394 Ala/Thr, is linked to risks of
human tumors. NPAS2 394 Thr is associated with reduced risk for non-
Hodgkin’s lymphoma66 and prostate cancer67 but increased risk for breast
cancer.68 In terms of effects on physiology,NPAS2 394 Thr correlates with
lower and bioavailable testosterone, providing support for a role for NPAS2
in hormone-related cancers.69 Another intronic SNP in NPAS2 has been
shown to be significantly associated with susceptibility to prostate cancer
as well.23
5. PER1
PER1 may be involved in circadian timing in human. A silent poly-morphism in PER1, 2434 T/C located in exon 18, is associated with
extreme diurnal preference.70 The C allele is more frequent in individuals
with extreme morning preference than in individuals with extreme evening
preference.
PER1 is believed to regulate alcohol consumption under psychosocial
stress. A SNP in the promoter region of PER1 is associated with frequency
of heavy drinking in adolescents, and significant interaction is observed
between this SNP and social adversity on drinking measures.71 Consistently,
this SNP is associated with alcohol dependence in adults as well. Molecular
analysis revealed that cortisol-induced transcriptional activation of PER1 is
reduced in human cell lines carrying the risk allele of this SNP. Binding
affinity of the transcription factor SNAIL1 to PER1 promoter containing
the risk allele is also reduced. Furthermore, mPer1 mutant mice show
increased alcohol consumption relative to wild type in response to social
defeat, supporting a role for PER1 in regulating alcohol drinking induced
by psychosocial stress.
Two intronic variants of PER1 significantly correlate with susceptibility
to prostate cancer.23 One of these SNPs is also significantly associated with
autistic disorder, along with a couple additional intronic SNPs.64 PER1 962
Ala/Pro variant is linked to serum levels of sex steroid and insulin-like
growth factor-binding protein 3, providing physiological support for a role
of PER1 in hormone-related cancer.69
6. PER2
PER2 is the first gene found to carry mutation that causes FASP. FASPis formerly known as familial advanced sleep phase syndrome and currently
59Phenotypic Effects of Human Clock Polymorphismsreferred to as familial advanced sleep phase disorder. However, according to
American Academy of Sleep Medicine’s classification of sleep disorders,
advanced and delayed sleep phase (DSP) is only a disorder when it is prob-
lematic for the individual.72 Therefore, in this chapter, advanced and DSP
phenotypes will not be called disorders. FASP is originally identified as a
highly penetrant autosomal dominant trait in three families in which affected
individuals exhibit very early sleep onset and offset time.73 HO¨ question-
naire was performed on family members, and FASP subjects scored signif-
icantly higher than unaffected relatives. FASP is early onset: the youngest
affected individual was 8 years old, and most FASP subjects knew they were
obligate “morning larks” by 30 years of age, which is distinctly different
from ASPD caused by aging.74,75 FASP subjects from the first identified
family demonstrate a 4-h phase advance of the time of sleep onset, sleep off-
set, first slow-wave sleep, and REM sleep compared to that of the controls,
although sleep quality and quantity are not significantly different between
the two groups. Narcolepsy, obstructive sleep apnea, “restless legs” syn-
drome, and depression were ruled out as possible causes of early sleep onset
in these FASP subjects. Consistent with the sleep–wake cycle, dim-light
melatonin onset, a reliable marker of circadian phase, and core body tem-
perature rhythms are also advanced by approximately 4 h in FASP subjectsFigure 3.1 Free-running period of sleep/wake and body temperature cycles in a FASP
subject. Sleep/wake (A) and body temperature (B) rhythms of a 69-year-old femalemon-
itored in time isolation for 18 days. The data are double plotted. (A) Filled bars indicate
periods of sleep derived from polygraphically-recorded sleep scored using “standard”
criteria. (B) Filled bars indicate periods when body temperature is below the daily mean.
The free-running period of both variables are 23.3 h based on chi-squared periodogram.
Adapted from Ref. 73.
60 Luoying Zhang et al.from this family. Sleep–wake and temperature rhythms of one FASP subject
were monitored in time isolation and show a circadian period of 23.3 h
(Fig. 3.1), which is substantially shorter than that of control subjects
(24.2 h) and is consistent with the advanced phase of sleep–wake cycle.
In order to identify the mutation that leads to FASP in the subjects in this
family, linkage analysis was performed, which mapped the allele to chromo-
some 2qter.76 Further physical mapping was carried out and led to identi-
fication of 40 cDNAs localized to this region. The only coding
mutation identified is in the PER2 cDNA at position 2106 (A–G), which
results in substitution of a serine at amino acid 662 with a glycine
(S662G). Functional characterization was subsequently carried out to estab-
lish whether the S662G mutation causes FASP. In vitro study using PER2
truncation mutants demonstrates that S662 is located within CK1-binding
region and the S662G mutation causes hypophosphorylation by CK1.
Sequence analysis of PER2 reveals four additional serine residues that are
C-terminal to S662 and each with two amino acids in between (i.e.,
S665, S668, S671, and S674), consistent with the CK1 recognition consen-
sus motif. Furthermore, mutating S662 to aspartate (S662D), which mimics
a phosphoserine, restores CK1-dependent phosphorylation, suggesting that
S662 is a phosphorylation site on PER2. Similarly, in vitro phosphorylation
assays using PER2 peptides that encompass residues from 660 to 674 dem-
onstrate that PER2 peptide with a phosphate covalently linked to S662 is
phosphorylated at the other residues by CK1, whereas PER2 peptide with-
out a phosphate at S662 is not phosphorylated by CK1.77 A quantitative
assay using PER2 peptides shows that an additional 4 mol of phosphate were
incorporated per mole of the PER2 peptide, corresponding to the four ser-
ine residues C-terminal to S662. Subsequent phosphoamino acid analysis
revealed that the threonine and tyrosine residues on the peptide are not
phosphorylated, implying that phosphorylation occurs at the serine residues.
Taken together, these results suggest that phosphorylation at S662 of PER2
serves as a priming event that is critical for a cascade of phosphorylations
downstream of S662 by CK1.
To investigate the functional consequences of the S662G mutation
in vivo, transgenic mice carrying wild-type hPER2 and hPER2 with
S662G or S662Dmutations were generated using a human bacterial artificial
chromosome (BAC) which carries the cis-acting genomic regulatory ele-
ments that can faithfully recapitulate endogenous PER2 expression.77
Behavior analysis shows that the S662G transgenic mice exhibit 2 h
shorter free-running period, whereas the S662D mice exhibit 0.5 h
61Phenotypic Effects of Human Clock Polymorphismslengthening of period versus wild type. Under 12 h light:12 h dark
(12L:12D) conditions, the S662G mice show 4 h phase advance of loco-
motor activity rhythms which is almost identical to that of human FASP sub-
jects carrying this mutation. The S662G mutation does not significantly
affect PER2 degradation or nuclear localization, but it affects PER2 tran-
script levels. In the transgenic mice, both hPER2 and the endogenous mouse
Per2 (mPer2) mRNA levels peak earlier for S662G and later for S662D rel-
ative to wild type, corresponding to the shorter and longer behavioral
periods, respectively. Moreover, the mRNA levels are lower in S662Gmice
and higher in S662D mice compared to wild type. Because both mutant
hPER2 and the endogenous wild-type mPer2 transcript levels are reduced
in the S662G mice, this argues for reduced transcriptional activity rather
than reduced PER2 mRNA stability as a result of the mutation.
Consistently, association studies have linked PER2 to diurnal preference
as well. The allele frequency of a SNP in the 50-UTR 12 bases upstream of
the translational start codon of PER2, -111G, is significantly higher in
individuals with extreme morning preference than individuals with extreme
evening preference.78 Based on computer prediction, this polymorphism
may alter the secondary structure of PER2 mRNA. A missense variant
1244 Gly/Glu is also associated with morningness: carriers of 1244 Gly
show significantly higher morning scores based on composite scale for
morningness.79 This 1244 Gly/Glu SNP is also part of a haplotype in
PER2 linked to depression vulnerability.80 In addition, PER2 has been
implicated in sleep regulation. A synonymous SNP in PER2, 2229 G/A,
correlates with the duration of sleep for nurses on day shift but not night
shift.61
The PER2 -111G allele is also linked to reduced activity in adolescents in
the key neural component of the reward circuitry (medial frontal cortex).81
Supporting the idea of a role for PER2 in reward function, mPer2 mutant
mice exhibit hypersensitized response to cocaine and strong cocaine-
induced place preference.82 Collectively, these results strongly suggest that
PER2 modulates reward.
The PER2 -111G/C SNP correlates with metabolic and eating behavior-
related phenotypes, including abdominal obesity, probability of withdrawing
fromweight-reduction program, extreme snacking, stress with dieting, eating
when bored, and skipping breakfast.83 Among individuals withmetabolic syn-
dromes and high levels of saturated fatty acid (SFA), -111G carriers have higher
plasma lipid concentrations,84 suggesting that the -111G/C allele interacts
with plasma SFA to modify lipid levels.
62 Luoying Zhang et al.PER2 participates in modulating alcohol consumption, similar to its
counterpart PER1. A SNP located in intron 3 of PER2, 10,870 A/G, is asso-
ciated with the quantity of alcohol intake.85,86 This SNP resides in a CAT-
TTTmotif, which is conserved in human, chimpanzee, and rat.85 It is also in
an enhancer-like structure, which contains several transcriptional factor-
binding site motifs. This SNP alters the binding motifs for Sp1, c-myb,
and NF-kB, possibly resulting in altered transactivation of PER2. mPer2
mutant mice exhibit increased alcohol consumption, accompanied by
enhanced glutamate levels in the extracellular space in the brain. This is
believed to be a result of reduced expression of the glutamate transporter
gene, Eaat1, and thus reduced uptake of glutamate by astrocytes.
Acamprosate, a drug used to prevent craving and relapse in alcoholic
patients, reduced the enhanced glutamate levels and normalized the
increased alcohol intake in mPer2mutant mice. Collectively, these data sug-
gest that PER2 acts to suppress glutamatergic signaling, which in turn influ-
ences alcohol drinking. Besides being involved in modulating alcohol
consumption, the PER2 10870 A/G SNP is also associated with SAD.24
PER2 is linked to the risk of cancer. An intronic SNP in PER2 is signif-
icantly associated with susceptibility to prostate cancer,23 whereas the afore-
mentioned 1244 Gly/Glu associated with morningness and depression
vulnerability also correlates with the risk of breast cancer in combination
with an SNP in CLOCK.59
7. PER3
Several polymorphisms in PER3 have been suggested to contribute todetermination of diurnal preference and DSP.63,87–91 The most well-studied
polymorphism among these is a polymorphic repeat region with four or five
copies of a 54-bp repetitive sequence (4-repeat vs. 5-repeat) in exon 18.
However, this association with morningness/eveningness attenuates with
age.90,92 Human subjects homozygous for the long allele are particularly sen-
sitive to blue-enriched light, as such light significantly suppresses evening
rise of endogenous melatonin in homozygotes for the long allele but not
the short allele.93 Likewise, individuals homozygous for the long allele
exhibit more pronounced response to the alerting effects of light compared
to homozygotes for the short allele.Waking electroencephalographic (EEG)
activity in the theta range (5–7 Hz), which is a putative correlate of sleep-
iness, is substantially attenuated during exposure to blue-enriched light in
subjects homozygous for the long allele but not the short allele. This length
63Phenotypic Effects of Human Clock Polymorphismspolymorphism has also been shown to be one of the alleles associated with
self-reported adaptation levels to shift-work schedules and sleep phase in
nurses working on shifts.61 Another SNP reported to be associated with
morning–evening scores is PER3 647 Val/Gly.63 A few polymorphisms
in the promoter region of PER3 are linked to DSP as well.91 In vitro studies
demonstrate that these promoter polymorphisms may modify the transcrip-
tion of PER3.
PER3 may exert effects on sleep homeostasis. Individuals homozygous
for the 5-repeat allele exhibit increase in markers of sleep homeostasis,
including slow-wave sleep, EEG slow-wave activity (0.75–4.5 Hz) in
non-REM sleep, as well as theta and alpha activity (8–12 Hz) during
REM sleep and wakefulness.94 The decrement in cognitive performance
as a result of sleep deprivation is significantly larger in subjects homozygous
for the long allele. Individuals of this genotype also performworse on tests of
executive function at early morning during sleep deprivation relative to
homozygotes for the short allele.95 Further study employing functional mag-
netic resonance imaging indicates that both genotypes recruit brain regions
typically involved in working memory, but individuals homozygous for the
short allele recruit supplemental anterior frontal, temporal, and subcortical
regions in addition.96 In contrast, widespread reductions of activation in pre-
frontal, temporal, parietal, and occipital areas were observed in homozygotes
for the long allele. Accompanying increased slow-wave sleep in subjects
homozygous for the long allele is an elevated sympathetic predominance
and a reduction of parasympathetic predominance in the autonomic nervous
system.97 Both homozygosity for the long allele and a SNP in exon 18, 1148
Arg, are associated with reduced daytime sleepiness, and also sleepiness in
nurses working during shifts.61,98 On the other hand, homozygosity of
the 4-repeat allele correlates with insomnia in alcohol-dependent patients.99
Consistent with the idea of a role for PER3 in modulating sleep homeostasis
in human, mice deficient for Per3 exhibit altered patterns of sleep both under
baseline condition and after sleep deprivation.100
A role for PER3 has been implicated in metabolic processes. PER3 639
Val is associated with T2D, while the much studied PER3 length polymor-
phism modifies the effects of the timing and duration of sleep on BMI.98,101
This is supported by in vitro study that demonstrates PER3 functions to
inhibit adipogenesis, and Per3 knockout mice display increased adipose tis-
sue and decreased muscle tissue relative to wild type.102
An intronic SNP in PER3 is significantly associated with susceptibility to
prostate cancer.23 At a physiological level, the aforementioned 5-repeat
64 Luoying Zhang et al.allele correlates with higher levels of serum insulin-like growth factor-I
(IGF) and the ratio of IGF-I to IGF-binding protein 3, which may contrib-
ute to hormone-related cancer.69 Furthermore, inflammation is an
established cancer risk factor and carriers of the 5-repeat allele show elevated
levels of the cytokine interleukin-6.103
Lastly, the 4-repeat allele of PER3 is significantly linked to heroin depen-
dence and postpartum onset of BP.104,105
8. CRY1
Two SNPs located in the promoter region of CRY1 are associatedwith susceptibility to and mortality from prostate cancer, respectively.23,106
On the other hand, a SNP within 30-UTR of CRY1 correlates with risk of
breast cancer.59 In addition, a SNP located 30 downstream of CRY1 is sig-
nificantly associated with MDD.
9. CRY2
CRY2 has been suggested by various studies to act as a modulator ofcancer development. Two intronic SNPs in CRY2 are significantly associ-
ated with susceptibility to prostate cancer.23,67 For one of these SNPs located
in intron 2, rs1401417 G/C, carriers of the C allele exhibit 1.7-fold
increased risk of prostate cancer.67 This risk is increased to 4.1-fold in the
C allele carriers with higher insulin resistance. This allele is also linked to
breast cancer risk, along with two additional SNPs, and all three of these
SNPs are significantly associated with the risk of non-Hodgkin’s lym-
phoma.59,107,108 Breast cancer patients have significantly higher levels of
CRY2 promoter methylation relative to controls, consistent with lower
levels ofCRY2 in tumor tissues compared to adjacent normal tissues.108 Fur-
thermore, in vitro analysis identifies alterations in the expression of breast
cancer-relevant genes, immune response genes, and hematologic system
development genes in response to CRY2 knockdown.107,108 Some of these
genes are predicted to have significant effects on several disease processes,
including cancer.107 Taken together, these findings suggest that CRY2
may exert significant effects on cancer susceptibility.
Genome-wide association study identified an intronic SNP in CRY2 to
be significantly associated with fasting glucose levels in nondiabetic adults.109
Subsequent studies reported this locus to be correlated with T2D, as well as
fasting glucose in healthy children and adolescents.110,111
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the SNPs that have been reported to be associated with the risk of breast
cancer and non-Hodgkin lymphoma.112 Molecular analysis revealed that
the levels of CRY2 mRNA are decreased in depressed bipolar patients.
While a night of total sleep deprivation results in significant upregulation
of CRY2 transcript in control subjects, it fails to do so in depressed bipolar
patients. Both the genetic andmolecular studies suggest that dysregulation of
CRY2 expression may be involved in vulnerability to depression.10. REV-ERBa
REV-ERBa is primarily implicated in BP. A haplotype comprised of
two SNPs located in intron 1 and 50-UTR of REV-ERBa, respectively, is
significantly associated with BP.113 Furthermore, a SNP in the intronic
region ofREV-ERBa, rs2314339 C/T, is associated with long-term efficacy
of lithium carbonate therapy in BP.114 The frequency of the T allele is sig-
nificantly increased in nonresponders, and patients carrying the T allele are
3.5more likely to show no improvement or even worsening of the illness.
Consistently, another SNP located in the promoter region of REV-ERBa
correlates with good treatment response and changes in REV-ERBa
expression in response to lithium treatment.115 These findings support a role
for REV-ERBa in the therapeutic mechanism of lithium.11. CK1«
A SNP in the 30-UTR of CK1e is significantly associated with self-
reported response to D-amphetamine.116 Consistently, quantitative trait loci
(QTL) analysis in mice selectively bred for high versus low sensitivity to
methamphetamine identified a QTL in the Ck1e gene that may cause the
difference in response to methamphetamine.117 Expression differences of
Ck1e is also observed in mouse lines displaying high versus low sensitivity
to methamphetamine. Collectively, human and animal studies suggest that
CK1e contributes to variability in stimulant response.
An intronic SNP of CK1e is linked to BP and prostate cancer.23,43 Fur-
thermore, another variant in CK1e correlates with testosterone to dihydro-
testosterone ratio in the serum, which may contribute to the pathology of
prostate cancer.69
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Exon sequencing of circadian genes for individuals that belong to amoderate-sized family with FASP led to the identification of a second muta-
tion that causes FASP. The mutation is a threonine-to-alanine alteration at
amino acid 44 of CK1d (CK1d-T44A), and this threonine is conserved in
other mammalian CK1s and Drosophila CK1 (dDBT).14 In vitro kinase assay
demonstrates that this mutation results in decreased phosphorylation of both
exogenous substrates (phosvitin and alpha-casein) and circadian substrates
(PER1–3). To examine the effects of this mutation on circadian rhythms
in vivo, BAC transgenic mice carrying either the wild type (hCK1d-WT)
or the mutant (hCK1d-T44A) hCK1d were generated. The behavioral
period under free-running condition is significantly shorter in the mutant
transgenic mice compared to wild type, consistent with the phase-advanced
phenotype of human subjects carrying this mutation. NeitherCK1dþ/ nor
hCK1d-WT transgenic mice exhibit altered period, suggesting that the
period is not affected by wild-type CK1d gene dosage. Thus, the shorter
period observed in hCK1d-T44A transgenic mice is likely due to the
T44Amutation and not alteredCK1d gene dosage. Interestingly, expression
of hCK1d-T44A in Drosophila circadian neurons results in longer period
compared to expression of hCK1d-WT. This may reflect differences in
the regulatorymechanism of themammalian clock versus invertebrate clock.
The aforementioned hPER2-S662G and hCK1d-T44Amutations indi-
cate that phosphorylation of PER2 by CK1 is critical for circadian timing in
humans. To characterize the functional relevance of the interaction between
PER2 and CK1 in vivo, hPER2 transgenic mice were crossed with both
hCK1d-WT transgenic and CK1d knockout mice.77 As described earlier
in this chapter, hPER2-S662G transgenic mice exhibit a short period of
22 h, whereas neither hCK1d-WT transgenic nor CK1dþ/ exhibits
altered circadian period. However, in mice carrying both hPER2-S662G
and hCK1d-WT transgenes, the period is shorter than hPER2-S662G single
transgenic animals by over 1 h. Consistently, expressing hPER2-S662G on
the CK1dþ/ background slightly lengthens the period compared to
expressing hPER2-S662G on a wild-type background. On the other hand,
hPER2-S662D transgenic mice, which show long period on wild-type
background, exhibit even longer period in CK1dþ/ background and a
shorter period in hCK1d-WT background. Therefore, decreasing CK1d
dosage lengthens period for both hPER2-S662G and hPER2-S662D
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nous period of both S662 mutants but not wild type.
Taken together, these results lead to the proposal of the following model
regarding how CK1 acts on PER2 to regulate circadian period: CK1 phos-
phorylates the serine residues downstream of S662 on PER2 after S662 is
phosphorylated by a priming kinase. Phosphorylation in this region of
PER2 increases PER2 mRNA and thus protein, while CK1 likely phos-
phorylates some other site(s) that results in degradation of PER2. The net
effect of these two opposing processes determines the level of PER2 and
in turn sets circadian period. In wild-type background, the balance of these
opposing effects can be maintained, thus decreasing or increasing CK1d
gene dosage does not change the period. In the presence of S662Gmutation,
the S662 residue can no longer be phosphorylated by the priming kinase,
leading to hypophosphorylation of the downstream residues by CK1.
Therefore, the net effect of CK1 on mutant PER2 results in reduced
PER2 levels and shorter period. DecreasingCK1d gene dosage partially sup-
presses the period shortening effect by reducing phosphorylation-mediated
PER2 degradation, whereas increasing CK1d gene dosage further shortens
period by enhancing phosphorylation-mediated PER2 degradation.
13. CUL1
A SNP in intron 3 ofCUL1 is significantly associated with rheumatoidarthritis (RA).118 In lymphocytic cell lines, this SNP affects transcriptional
efficiency of CUL1 promoter activity. CUL1 is highly expressed in lym-
phoid tissues, and suppression of CUL1 inhibits IL-8 induction, which plays
an important role in migration of inflammatory cells into the affected area as
seen in RA. Therefore, this SNP in intron 3 of CUL1 could be affecting
susceptibility to RA by modulating expression levels of CUL1. In another
independent study, this SNP, along with two other, constitutes a haplotype
that is significantly associated with RA and response to methotrexate treat-
ment, a commonly prescribed drug for RA patients.119
14. b-TrCP
b-TrCP mutations have been implicated in cancer. Missense somatic
mutations in b-TrCPwere identified in gastric cancers.120 In tissues carrying
these mutations, b-catenin levels are increased with aberrant subcellular
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Further evidence came from an association study demonstrating that a
9-bp deletion polymorphism in the 30-UTR of b-TrCP correlates with
reduced risk of hepatocellular carcinoma (HCC).121 Molecular analysis rev-
ealed that HCC tumor tissues with the deletion display reduced levels of
b-TrCP compared to those that do not carry the deletion. Because b-TrCP
is believed to be oncogenic, reduced b-TrCP levels associated with the dele-
tion variant could explain the reduced risk of HCC. Additionally, duplica-
tion of b-TrCP gene is associated with split hand-split foot malformation.122
15. DEC1
DEC1 was identified as one of the genes located in a commonlydeleted chromosomal region in a wide panel of esophageal squamous cell
carcinoma.123 DEC1 transcript levels were significantly reduced in the
majority of esophageal cancer cell lines, while introducing DEC1 cDNA
into cancer cells that lack DEC1 expression significantly suppresses cell
growth. Consistently, a polymorphism in the promoter region of DEC1
(-249T/C) is significantly associated with the risk of squamous cell carci-
noma of the head and neck (SCCHN), and human subjects homozygous
for -249 C show significantly reduced susceptibility to SCCHN.124
In silico analysis predicts that the -249 T to C change leads to a gain of a tran-
scription factor-binding site. Indeed, further functional analysis demon-
strated that the T–C change results in increased transcriptional activity at
DEC1 promoter and enhanced protein-DNA binding. In summary, these
results suggest that DEC1 functions as a tumor suppressor and genetic var-
iations in DEC1 could alter susceptibility to cancer.
16. DEC2
The first human mutation identified to cause a sleep homeostasis phe-notype is inDEC2.125 Individuals carrying a proline to arginine mutation at
amino acid position 384 (P384R) of DEC2 have approximately 2-h shorter
sleep time per 24-h day compared to family members who do not carry the
mutation (Fig. 3.2). Studies in cell culture demonstrated that the P384R
mutation results in attenuated DEC2 repressor activity of CLOCK/
BMAL1-driven transcription.
To validate that the P384R mutation is indeed causing the short-sleep
phenotype and not merely associated with the phenotype, BAC transgenic
Figure 3.2 Activity recording of a DEC2-P384R mutation carrier. Filled bars indicate
periods of activity by wrist actigraphy. Extended periods of activity can be observed.
Adapted from Ref. 125.
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P384R. hDEC2-P384R mice do not exhibit altered free-running period,
but the duration of the activity period (alpha) is 1.2-h longer relative to
hDEC2-WT transgenic, wild-type littermates, and Dec2 knockout mice.
This recapitulates the shorter sleep duration (i.e., inactive period) phenotype
observed in humans. Moreover, when hDEC2-P384R is expressed in a
Dec2 knockout background, alpha is further lengthened to 2.5 h longer
than controls.
To examine the effects of the DEC2-P384R mutation on sleep, EEG
and electromyography were performed on mutant transgenic mice and lit-
termate controls. hDEC2-P384Rmice were awake for a significantly longer
period of time during the light phase compared to wild type, accompanied
by significant reduction of both NREM and REM sleep. Analysis of sleep
architecture demonstrated decreased wake duration and an increase in the
number of wake episodes in hDEC2-P384R mice relative to wild type.
In addition, these animals exhibited significantly moreNREMepisodes dur-
ing the light phase, but each episode is shorter in duration. These results
indicate that sleep (in particular NREM sleep) is more fragmented in
hDEC2-P384R mice than that of wild type. To better understand the role
of DEC2 in sleep regulation, hDEC2-P384Rmice and wild-type littermates
were subjected to acute sleep deprivation. hDEC2-P384Rmice showed sig-
nificantly less rebound in both NREM and REM sleep, and a slower recov-
ery of acute sleep loss. hDEC2-P384R mice also exhibited lower NREM
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which indicates that the depth of the rebound of NREM sleep is affected in
hDEC2-P384R animals. Consistent with the mammalian data, expressing
mDec2-P384R in the sleep/rest center of Drosophila brain leads to signifi-
cantly less sleep-like behavior with decreased sleep bout duration and
increased sleep bout number versus flies expressing mDec2-WT. In sum-
mary, these results demonstrate DEC2 as an important player in the regu-
lation of sleep homeostasis.
17. TIMELESS
TIMELESS is associated with depression and sleep disturbances.126Four SNPs in or near the TIMELESS gene are linked to depression with
fatigue in females, while two of these SNPs (rs7486220 A/G and
rs1082214 C/T) are also linked to depression with early morning awakening
in males. Notably, rs7486220 A and rs1082214 C correlate with depression
with fatigue in females, whereas rs7486220 G and rs1082214 T correlate
with depression with early morning awakening in males. In a separate set
of individuals that do not have depression, rs1082214 C is correlated with
higher levels of seasonal changes in mood in females, while rs1082214
T is correlated with early morning awakening and fatigue in males. Collec-
tively, these data implicate a connection between TIMELESS and gender-
dependent depression and sleep regulation.
18. CONCLUDING REMARKS
Studies of human clock-gene variants reveal that besides circadiantiming, clock genes may also be involved in a number of other biological
processes (Table 3.1). Most of the clock-gene polymorphisms are associated
with sleep regulation, cancer development, metabolic traits, and mood dis-
orders, implying that these processes may have particularly close connections
with the circadian clock, and thus are more sensitive to alterations of the
clock caused by genetic variations. In addition, CLOCK, PER1–3, and
CK1e polymorphisms are linked to addiction, suggesting a role for the clock
in reward circuitry of the brain. BMAL1 and NPAS2 polymorphisms are
related to fertility and seasonal variations, supporting the long-held view that
circadian clock participates in seasonal adaptability. Furthermore, studies
using mice deficient for clock genes verified the involvement of clock genes
Table 3.1 Genetic associations between the clock genes and human phenotypes
Gene Human phenotype associated
Phenotype of mutant mouse
model
BMAL1 Type 2 diabetes and hypertension Hypoinsulinemia and diabetes
Prostate cancer
Seasonal affective disorder
Number of pregnancies and
miscarriages
Infertility
Alcohol consumption
CLOCK Eveningness preference Circadian phenotype
Altered sleep Reduced sleep
Bipolar disorder, schizophrenia,
attention deficit hyperactivity
disorder, and fluvoxamine response
in major depressive disorder patients
Mania-like behavior
Metabolic traits, hypertension, and
nonalcoholic fatty liver disease
Obesity and metabolic
syndromes
Prostate cancer, breast cancer, and
survival rate of colorectal cancer
NPAS2 Daily timing and sleepiness Reduced sleep and enhanced
light entrainment
Seasonal affective disorder and
depression
Autistic disorder
Chronic fatigue syndrome
Number of miscarriages
Non-Hodgkin’s lymphoma,
prostate cancer, and breast cancer
PER1 Extreme morning preference Circadian phenotype
Alcohol consumption under
psychosocial stress
Increased alcohol consumption
in response to social defeat
Prostate cancer
Autistic disorder
PER2 Familial advanced sleep phase Phase advance during light/
dark cycle and shorter free-
running period
Morningness preference
Duration of sleep (nurses on
day shift)
Depression
Reduced activity in medial frontal
cortex of adolescents
Hypersensitized response to
cocaine and strong cocaine-
induced place preference
Metabolic traits
Alcohol consumption Increased alcohol consumption
Seasonal affective disorder
Prostate cancer and breast cancer
Continued
Table 3.1 Genetic associations between the clock genes and human
phenotypes—cont'd
Gene Human phenotype associated
Phenotype of mutant mouse
model
PER3 Morningness/eveningness
preference, timing of sleep phase,
and sensitivity to blue-enriched
light
Sleep homeostasis phenotypes Altered sleep patterns
Type 2 diabetes and body mass
index
Increased adipose tissue and
decreased muscle tissue
Prostate cancer
Heroin dependence
Postpartum onset of bipolar
disorder
CRY1 Prostate cancer and breast cancer
Major depressive disorder
CRY2 Prostate cancer, breast cancer, and
non-Hodgkin’s lymphoma
Fasting glucose levels
Winter depression
REV-
ERBa
Bipolar disorder and efficacy of
lithium treatment in bipolar
disorder
CK1e Self-reported response to D-
amphetamine
A quantitative trait locus in
Ck1e may cause differences in
response to methamphetamineBipolar disorder
Prostate cancer
CK1d Familial advanced sleep phase Shorter free-running period
CUL1 Rheumatoid arthritis and response
to methotrexate treatment
B-TrCP Gastric cancers and hepatocellular
carcinoma
Split hand-split foot malformation
DEC1 Squamous cell carcinoma of the
head and neck
DEC2 Shorter sleep duration Reduced sleep amount
TIMELESS Depression and sleep
disturbances
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73Phenotypic Effects of Human Clock Polymorphismsin a number of the processes implicated by human genetic studies, including
sleep, metabolic syndromes, mood disorders, addiction, and fertility.
It is worthwhile at this point to detail approaches to Mendelian genetics
versus association studies as the distinction between the two is not well
understood by many people who are interested in the current topic. Men-
delian genetics deals with identification of genetic variants of strong effect
and are sufficient to cause a phenotype. For example, genetic studies of
rodents with spontaneous mutations (e.g., the Ck1e mutant hamster) and
forward genetic screens in model organisms where mutagenesis is performed
and animals are screened for a phenotype (e.g., short/long period or arrhyth-
mia) are focused on identifying the genes andmutations which cause the phe-
notype. Similar studies have been successful in humans where identification
of FASP allowed cloning of causative genes and mutations.
In complex genetics, genetic variants are sought where there is a statis-
tical association of the variant with a phenotype. The variant itself is only
associated with an increased risk of the phenotype. Thus, having the variant
does not mean that the carrier will have the phenotype. Neither does it mean
that one without the variant cannot have the phenotype. Such a finding does
not simply imply that variant is itself causative of the increased risk. Rather, it
suggests that the associated variant and/or a genetic variant in the vicinity of
the associated variant leads to increased risk. Consequently, we must be very
careful when interpreting these data, as many such findings (positive associ-
ations) have (or will turn out to be) false positives. In some cases, a variant in a
genewill be associatedwith the phenotype because that gene is truly linked to
the biology underlying the phenotype of interest. In other cases, a genetic
variant may truly be associated with the phenotype but only because it is
in linkage disequilibrium with a variant in another gene. Mutations in some
clock genes have been generated and result in behavioral and/or physiolog-
ical phenotypes in animal models (such as the mouse studies described earlier
in this chapter). These studies support the argument that the recognized clock
gene associations in humans with similar or related phenotypes occur as a
result of genetic variants in the respective clock genes. To validate whether
these genetic variations found by the association studies lead to phenotypic
changes will require generation and characterization of appropriate animal
models carrying equivalent polymorphisms. Unlike Mendelian traits with
very prominent phenotypes as in the cases of FASP, however, many of the
behavioral and physiological phenotypes observed in association studies are
relatively subtle and may exhibit complex allelic interactions, imposing great
complications and challenges on studies in animal models. Nevertheless, as
74 Luoying Zhang et al.we learn more regarding the molecular underpinnings of the biological pro-
cesses involved and as our phenotyping techniques improve, using animal
models to investigate themechanistic alterations caused by these human clock
gene variants will become more effective and fruitful.
In the past few decades, much effort has been devoted into understanding
what constitutes the circadian clock and how the clock functions. Thus, we
currently have a handful of “clock genes” and a relatively clear picture of the
molecular mechanisms regarding how these genes act together to set the
phase and amplitude of the clock. One of the next big challenges in the field
is answering the “why” question, that is, why is the clock built this way, or an
even more fundamental question, why do we need a clock. At the individual
level, investigating the broad consequences of alterations in clock genes will
help us understand the function of the clock and the role it plays in our over-
all well-being. At a population level, studying the distribution of clock geno-
types and associated phenotypes across the world will facilitate unveiling the
interactions between the molecular clock and environment. Insights gained
from these studies shall provide answers to some of the most fundamental
questions in human circadian biology. Only with such understanding can
we maximize the health benefits and therapeutic values of the circadian
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